跳至主要内容
临床试验/NCT05037058
NCT05037058Unknown不适用

China Diabetes Cardiovascular Initiative

Beijing Institute of Heart, Lung and Blood Vessel Diseases0 个研究点目标入组 9,600 人开始时间: 2021年9月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
9,600
主要终点
Proportion of patients receiving guidance on individualized physical activity

研究概览

简要总结

As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients hospitalized with acute coronary syndrome and diabetes.
  • Aged at least 18 years.

排除标准

  • 未提供

结局指标

主要结局

Proportion of patients receiving guidance on individualized physical activity

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients with body height and weight measured and documented

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients receiving guidance on individualized dietary

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of STEMI patients receiving reperfusion therapy by PCI

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of NSTE-ACS patients receiving risk stratification at admission

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients prescribed dual antiplatelet medications at discharge

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients with indications prescribed a beta-blocker at discharge

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients prescribed a statin at discharge

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients with indications prescribed an ACE-I or ARB at discharge

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients that receiving an LDL-C assessment

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients with evaluation for LV systolic function by echocardiography

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of smoking patients that receiving smoking cessation advice/counseling

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients receiving fasting glucose test at least twice

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients receiving HbA1C test

时间窗: Duration of hospital stay, an expected average of 1 week

Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit

时间窗: Duration of hospital stay, an expected average of 1 week

次要结局

未报告次要终点

研究者

发起方
Beijing Institute of Heart, Lung and Blood Vessel Diseases
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dong ZHAO

Professor of Beijing Institute of Heart, Lung and Blood Vessel Diseases

Beijing Institute of Heart, Lung and Blood Vessel Diseases

相似试验